Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Belimumab for the prophylaxis of chronic GvHD

John DiPersio • 23 Apr 2022
The 2022 Tandem Meetings
General Antibodies Belimumab

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses the rationale for using belimumab for the prophylaxis of chronic graft-versus-host disease (cGvHD). By binding to the B-cell activating factor released by alloreactive T-cells, belimumab also blocks the activation of B-cells, which play an important role in cGvHD and cGvHD-related complications. A recent study showed that patients treated with belimumab have significantly lower rates of cGvHD and experienced no important side effects. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from John DiPersio

One big question with John DiPersio: what AML advance could transform frontline care in three years?
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
3:30
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
John DiPersio • 19 Sep 2025
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
1:14
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
John DiPersio • 19 Sep 2025
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
2:23
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
John DiPersio • 19 Sep 2025

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals